Gufic Biosciences Limited has informed the Exchange about Investor Presentation
GUFICBIO · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Gufic Biosciences reported Q3 FY26 revenue of Rs 231.1 Cr, up ~11% YoY, with 9M FY26 revenue at Rs 688.4 Cr versus Rs 614.8 Cr last year. However, profitability has come under pressure: 9M FY26 EBITDA margin fell to 15.72% from 18.15% a year ago, and PAT dropped to Rs 42.6 Cr from Rs 61.9 Cr. Management highlighted the new Indore lyophilized injectables facility, which began commercial production in October 2024 and is currently at 30% utilization with a stated path to EBITDA breakeven in FY26 and margin-accretive status by FY27. The company set a 3-5 year roadmap targeting 5-10% market share in identified EU, LATAM and ROW geographies, supported by Gufic Ireland's first EU marketing authorization and a partnership with a global health organization covering 109 public health markets. Growth levers span critical care, women's health (IVF), aesthetics (botulinum toxin), and chronic care, with 150+ products in the global registration pipeline.
Short-term, investors should note the continued margin compression and weaker PAT despite revenue growth, but the Indore facility ramp-up and FY27 margin-accretive target, along with EU market entry and licensing deals, offer a credible medium-term growth and margin recovery story. Shareholders may watch capacity utilization at Indore and EU commercial traction closely as the next key triggers.